AR073689A1 - Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras. - Google Patents
Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.Info
- Publication number
- AR073689A1 AR073689A1 ARP090103709A ARP090103709A AR073689A1 AR 073689 A1 AR073689 A1 AR 073689A1 AR P090103709 A ARP090103709 A AR P090103709A AR P090103709 A ARP090103709 A AR P090103709A AR 073689 A1 AR073689 A1 AR 073689A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- mono
- heterocyclyl
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 title 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 title 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- -1 hydroxy, carboxyl Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1): en la que W es carbono y Y es nitrogeno o; W es nitrogeno y Y es carbono; Ar1 es carbociclo, heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno a tres Ra; Ar2 es carbociclo, heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno a tres Rb; R1 es hidrogeno, alquilo C1-6 o alcoxi C1-6-alquilo C1-6; cada uno de R2 y R3 es independientemente hidrogeno, alquilo C1-6 o alquenilo C1-6, donde el alquilo o alquenilo C1-6 está opcionalmente parcial o completamente halogenado o sustituido con uno a tres grupos seleccionados independientemente entre ciano, alcoxi C1-6, hidroxilo, -CO2-alquilo C1-6, -C(O)N(Re)(Rf), -N(Re)(Rf) y heterociclilo opcionalmente sustituido con oxo; Ra es alquilo C1-6, cicloalquilo C3-10, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, amino, mono- o di-alquilamino C1-6, cicloalquilamino C1-6, alquilaminocarbonilo C1-6, acilo C1-6, acilamino C1-6, dialquilaminocarbonilo C1-6, hidroxilo, halogeno, ciano, nitro, oxo, R4-S(O)m-NH-, R4-NH-S(O)m-, arilo o carboxilo; Rb es hidroxilo, carboxilo, halogeno, -(CH2)n-CN, -(CH2)n-CO2-alquilo C1-6, nitro, -SO3H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, alcoxi C1-6, alquil C1-6-(O)-, -(CH2)n-NRcRd, R4-S(O)m(CH2)0-1-, R4-S(O)m-NRe-, R4-NRe-S(O)m(CH2)0-1-, -NRf-C(O)-Re, -(CH2)x-C(O)-(CH2)n-NRcRd, heterociclilo, arilo o heteroarilo, cada Rb cuando sea posible está opcionalmente halogenado o sustituido con 1 a 3 alquilo C1-6, hidroxilo, acilo C1-6, alcoxicarbonilo C1-6, alquil C1-6-S(O)m-, arilo o carboxilo; cada Rc y Rd es independientemente hidrogeno, alquilo C1-6, acilo C1-6, cicloalquilo C3-10, alcoxi C1-6, hidroxialquilo C1-6, ciano-alquilo C1-6, alquil C1-6-alcoxi C1-6, alquilsulfonilo C1-6, alcoxicarbonil C1-6-alquilo C0-3, -(CH2)n-C(O)-NReRf o (CH2)n-NReRf; cada Re y Rf es independientemente hidrogeno, alquilo C1-6, cicloalquilo C3-10, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, mono- o dialquilamino C1-6-alquilo C1-6, hidroxialquilo C1-6 o acilo C1-6; R4 es hidrogeno, alquilo C1-6, cicloalquilo C3-6, heterociclil(CH2)0-1, mono- o di-alquilamino C1-6, mono- o di-alquilamino C1-6-(CH2)2-3N(Re)-, arilo o heteroarilo, cada uno opcionalmente sustituido con 1 a 3 alquilo C1-6, cicloalquilo C3-6, alcoxi C1-6, halogeno, hidroxilo, oxo, carboxilo, -C(O)NReRf, amino, mono- o di-alquilamino C1-6, alcoxicarbonilo C1-6, o acilamino C1-6; cada n, x es independientemente 0-3; cada m es independientemente 0-2; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10040108P | 2008-09-26 | 2008-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073689A1 true AR073689A1 (es) | 2010-11-24 |
Family
ID=41349302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103709A AR073689A1 (es) | 2008-09-26 | 2009-09-25 | Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US7879873B2 (es) |
| EP (1) | EP2346868B1 (es) |
| JP (1) | JP5507567B2 (es) |
| KR (1) | KR20110060904A (es) |
| CN (1) | CN102227425A (es) |
| AP (1) | AP2739A (es) |
| AR (1) | AR073689A1 (es) |
| AU (1) | AU2009296839A1 (es) |
| BR (1) | BRPI0919844A2 (es) |
| CA (1) | CA2737472A1 (es) |
| CL (1) | CL2011000668A1 (es) |
| CO (1) | CO6351735A2 (es) |
| EA (1) | EA201100524A1 (es) |
| EC (1) | ECSP11010932A (es) |
| IL (1) | IL210857A0 (es) |
| MA (1) | MA32655B1 (es) |
| MX (1) | MX2011002951A (es) |
| NZ (1) | NZ591115A (es) |
| PE (1) | PE20110854A1 (es) |
| TW (1) | TW201018683A (es) |
| UA (1) | UA103634C2 (es) |
| UY (1) | UY32140A (es) |
| WO (1) | WO2010036632A1 (es) |
| ZA (1) | ZA201100625B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| KR20110060904A (ko) | 2008-09-26 | 2011-06-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물 |
| AU2010224693B2 (en) * | 2009-03-19 | 2016-07-28 | Lifearc | Compounds |
| DK2491028T3 (da) | 2009-10-21 | 2014-01-13 | Boehringer Ingelheim Int | Indazol og pyrazolopyridine forbindelser som CCR1 receptor antagonister |
| EP2493875B1 (en) * | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| IN2012DN05081A (es) * | 2009-12-08 | 2015-10-09 | Boehringer Ingelheim Int | |
| EP2563787B1 (en) * | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| EP2388260A1 (de) * | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
| AR082885A1 (es) * | 2010-09-03 | 2013-01-16 | Genentech Inc | Compuestos y composiciones para la inhibicion de nampt |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CN102775365A (zh) * | 2011-05-10 | 2012-11-14 | 无锡立诺康医药科技有限公司 | 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺 |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| WO2013062945A1 (en) | 2011-10-24 | 2013-05-02 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| JP2015508785A (ja) * | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| AR091858A1 (es) * | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP2970306A4 (en) * | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| FR3016879A1 (fr) * | 2014-01-29 | 2015-07-31 | Guillaume Laconde | Procede de preparation de benzotriazole n-acyles |
| SI3119757T1 (en) | 2014-03-17 | 2018-08-31 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
| AP2016009403A0 (en) | 2014-04-14 | 2016-08-31 | Boehringer Ingelheim Int | Compounds as modulators of ror gamma |
| CA3002418C (en) | 2015-10-23 | 2023-10-03 | Vifor (International) Ag | Novel ferroportin inhibitors |
| WO2017081310A1 (en) | 2015-11-13 | 2017-05-18 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| BR112018009579A2 (pt) | 2015-11-13 | 2018-11-06 | Basf Se | composto da fórmula i, mistura, composição agroquímica, uso de composto e método de combate a fungos |
| JP6997095B2 (ja) | 2016-03-07 | 2022-02-03 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | 抗菌性化合物およびその使用 |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| CN111393376B (zh) * | 2020-05-11 | 2022-05-13 | 安徽赛迪生物科技有限公司 | 一种2-氯嘧啶-4-甲酸的合成方法 |
| WO2021262878A1 (en) * | 2020-06-24 | 2021-12-30 | Oregon Health & Science University | Novel molecule for modulation of innate immune responses controlled by sting protein |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242931A (en) * | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| CA1338625C (en) * | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| PL170567B1 (pl) | 1991-03-28 | 1997-01-31 | Eisai Co Ltd | Sposób wytwarzania pochodnych aminy heterocykliczno-cyklicznej PL PL PL PL PL PL PL PL |
| US5750542A (en) * | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| WO1994001415A1 (fr) * | 1992-07-03 | 1994-01-20 | Kumiai Chemical Industry Co., Ltd. | Derive heterocyclique condense et desherbant |
| BR9405488A (pt) * | 1993-06-25 | 1999-06-01 | Kumiai Chemical Industry Co | Derivado de indazolsulfoniluréia seu uso e intermediário para sua produção |
| US6025374A (en) * | 1994-12-06 | 2000-02-15 | Merck Sharp & Dohme, Ltd. | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) * | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| EA200000385A1 (ru) | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4) |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| ATE303988T1 (de) * | 1999-06-14 | 2005-09-15 | Lilly Co Eli | Inhibitoren von serin proteasen |
| AU5895500A (en) * | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| GB0030303D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7058826B2 (en) * | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| ES2338539T3 (es) * | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
| WO2003053941A2 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| EP1497278B1 (en) | 2002-04-11 | 2010-05-26 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic amide derivatives as cytokine inhibitors |
| IL164209A0 (en) * | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
| DK1531822T3 (da) * | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) * | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| US7371757B2 (en) * | 2003-08-15 | 2008-05-13 | Astrazeneca Ab | Fused heterocycles as inhibitors of glutamate racemase(MURI) |
| US7960417B2 (en) | 2005-02-24 | 2011-06-14 | Merck Sharp & Dohme Corp. | Benzazole potentiators of metabotropic glutamate receptors |
| GB0504828D0 (en) * | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| PT1881823E (pt) | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | Composições e métodos para o tratamento de transtornos oculares |
| US20070010523A1 (en) * | 2005-06-22 | 2007-01-11 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| AU2006287202B2 (en) | 2005-09-01 | 2013-01-24 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists |
| WO2007102883A2 (en) | 2005-10-25 | 2007-09-13 | Smithkline Beecham Corporation | Chemical compounds |
| TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| WO2009006404A2 (en) * | 2007-06-29 | 2009-01-08 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| EP2188295A4 (en) | 2007-08-10 | 2011-11-16 | Crystalgenomics Inc | PYRIDINE DERIVATIVES AND METHODS OF USE |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009085256A1 (en) * | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| JP5216912B2 (ja) * | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| KR20110060904A (ko) | 2008-09-26 | 2011-06-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물 |
| DK2491028T3 (da) | 2009-10-21 | 2014-01-13 | Boehringer Ingelheim Int | Indazol og pyrazolopyridine forbindelser som CCR1 receptor antagonister |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| IN2012DN05081A (es) * | 2009-12-08 | 2015-10-09 | Boehringer Ingelheim Int | |
| EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2009
- 2009-09-22 KR KR1020117006720A patent/KR20110060904A/ko not_active Withdrawn
- 2009-09-22 AU AU2009296839A patent/AU2009296839A1/en not_active Abandoned
- 2009-09-22 MX MX2011002951A patent/MX2011002951A/es active IP Right Grant
- 2009-09-22 JP JP2011529154A patent/JP5507567B2/ja active Active
- 2009-09-22 EP EP09792818.8A patent/EP2346868B1/en active Active
- 2009-09-22 NZ NZ591115A patent/NZ591115A/xx not_active IP Right Cessation
- 2009-09-22 AP AP2011005685A patent/AP2739A/xx active
- 2009-09-22 WO PCT/US2009/057778 patent/WO2010036632A1/en not_active Ceased
- 2009-09-22 US US12/564,129 patent/US7879873B2/en active Active
- 2009-09-22 CN CN2009801472064A patent/CN102227425A/zh active Pending
- 2009-09-22 PE PE2011000789A patent/PE20110854A1/es not_active Application Discontinuation
- 2009-09-22 BR BRPI0919844A patent/BRPI0919844A2/pt not_active IP Right Cessation
- 2009-09-22 CA CA2737472A patent/CA2737472A1/en not_active Abandoned
- 2009-09-22 UA UAA201105061A patent/UA103634C2/ru unknown
- 2009-09-22 EA EA201100524A patent/EA201100524A1/ru unknown
- 2009-09-24 UY UY0001032140A patent/UY32140A/es not_active Application Discontinuation
- 2009-09-25 AR ARP090103709A patent/AR073689A1/es unknown
- 2009-09-25 TW TW098132530A patent/TW201018683A/zh unknown
-
2010
- 2010-12-16 US US12/969,753 patent/US8063065B2/en active Active
-
2011
- 2011-01-25 IL IL210857A patent/IL210857A0/en unknown
- 2011-01-25 ZA ZA2011/00625A patent/ZA201100625B/en unknown
- 2011-03-17 CO CO11033549A patent/CO6351735A2/es active IP Right Grant
- 2011-03-24 MA MA33724A patent/MA32655B1/fr unknown
- 2011-03-25 CL CL2011000668A patent/CL2011000668A1/es unknown
- 2011-03-29 EC EC2011010932A patent/ECSP11010932A/es unknown
- 2011-10-14 US US13/273,509 patent/US8163918B2/en active Active
-
2012
- 2012-02-08 US US13/368,397 patent/US8338610B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UY32140A (es) | 2010-04-30 |
| US8063065B2 (en) | 2011-11-22 |
| US20100093724A1 (en) | 2010-04-15 |
| CL2011000668A1 (es) | 2011-10-28 |
| US8163918B2 (en) | 2012-04-24 |
| IL210857A0 (en) | 2011-04-28 |
| ZA201100625B (en) | 2011-09-28 |
| TW201018683A (en) | 2010-05-16 |
| UA103634C2 (en) | 2013-11-11 |
| AP2011005685A0 (en) | 2011-04-30 |
| CA2737472A1 (en) | 2010-04-01 |
| NZ591115A (en) | 2012-10-26 |
| US8338610B2 (en) | 2012-12-25 |
| CO6351735A2 (es) | 2011-12-20 |
| JP5507567B2 (ja) | 2014-05-28 |
| US20110086846A1 (en) | 2011-04-14 |
| US7879873B2 (en) | 2011-02-01 |
| US20120136158A1 (en) | 2012-05-31 |
| MA32655B1 (fr) | 2011-09-01 |
| BRPI0919844A2 (pt) | 2019-09-24 |
| JP2012503664A (ja) | 2012-02-09 |
| KR20110060904A (ko) | 2011-06-08 |
| AP2739A (en) | 2013-09-30 |
| AU2009296839A1 (en) | 2010-04-01 |
| PE20110854A1 (es) | 2011-12-23 |
| CN102227425A (zh) | 2011-10-26 |
| EA201100524A1 (ru) | 2011-10-31 |
| EP2346868A1 (en) | 2011-07-27 |
| MX2011002951A (es) | 2011-04-26 |
| WO2010036632A1 (en) | 2010-04-01 |
| US20120035370A1 (en) | 2012-02-09 |
| EP2346868B1 (en) | 2016-01-27 |
| ECSP11010932A (es) | 2011-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073689A1 (es) | Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras. | |
| CR9881A (es) | Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos | |
| PA8791601A1 (es) | Compuestos de biciclolactama sustituida | |
| ATE442847T1 (de) | Benzimidazol-derivate als mek-hemmer | |
| PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| AR060590A1 (es) | Compuestos imidazo | |
| UY30493A1 (es) | Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| CL2011002016A1 (es) | Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc). | |
| AR037771A1 (es) | Moleculas pequenas para el tratamiento del crecimiento celular anormal | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
| PE20040450A1 (es) | Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa | |
| AR060591A1 (es) | Compuestos imidazo | |
| ECSP109953A (es) | Derivados de piridazinona | |
| EA201200653A1 (ru) | Гетариламинохинолины | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| CL2009000324A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| CL2011001332A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica que los comprende; y su uso para el tratamiento del virus de la hepatitis c (vhc). | |
| PE20090772A1 (es) | Derivados de bencimidazol | |
| SV2007002397A (es) | Aminopiridinas como inhibidores de b-secretasa ref. am101663 | |
| AR057986A1 (es) | Compuesto heterociclico y su uso farmaceutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |